Theravance Biopharma (TBPH) Cash & Current Investments (2016 - 2025)
Theravance Biopharma (TBPH) has disclosed Cash & Current Investments for 12 consecutive years, with $177.2 million as the latest value for Q3 2025.
- On a quarterly basis, Cash & Current Investments rose 93.91% to $177.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $177.2 million, a 93.91% increase, with the full-year FY2024 number at $40.1 million, changed N/A from a year prior.
- Cash & Current Investments was $177.2 million for Q3 2025 at Theravance Biopharma, down from $338.8 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $486.8 million in Q3 2022 to a low of $40.1 million in Q4 2024.
- A 5-year average of $194.3 million and a median of $167.5 million in 2023 define the central range for Cash & Current Investments.
- Peak YoY movement for Cash & Current Investments: tumbled 72.47% in 2023, then surged 252.63% in 2025.
- Theravance Biopharma's Cash & Current Investments stood at $216.2 million in 2021, then soared by 51.46% to $327.5 million in 2022, then plummeted by 59.08% to $134.0 million in 2023, then crashed by 70.08% to $40.1 million in 2024, then surged by 341.92% to $177.2 million in 2025.
- Per Business Quant, the three most recent readings for TBPH's Cash & Current Investments are $177.2 million (Q3 2025), $338.8 million (Q2 2025), and $130.9 million (Q1 2025).